Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Advanced Solid Tumor 13Leukemia, Myeloid, Acute 10Carcinoma, Non-Small-Cell Lung 7Advanced Solid Tumors 7Breast Neoplasms 6Solid Tumor 5Pancreatic Neoplasms 5Melanoma 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Solid Tumors 3Recurrence 3Myelodysplastic Syndromes 3Lung Neoplasms 3Leukemia, Biphenotypic, Acute 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Biliary Tract Neoplasms 3Advanced Malignant Solid Tumor 3Advanced Lung Cancer 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

fludarabine phosphate 4Tacrolimus 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Filgrastim 3Cyclosporine 3fludarabine 2Whole-Body Irradiation 2Thiotepa 2Methylprednisolone 2Methotrexate 2Melphalan 2Cytarabine 2trametinib 1Stem Cell Transplantation 1Specimen Handling 1Sorafenib 1Sirolimus 1Mitoxantrone 1Methylprednisolone Hemisuccinate 1Isotretinoin 1Injections 1Granulocyte Colony-Stimulating Factor 1Cyclophosphamide 1Cord Blood Stem Cell Transplantation 1Clofarabine 1Busulfan 1Bone Marrow Transplantation 1Azacitidine 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myelomonocytic, Juvenile × Injections × Clear all
NCT05849662 2026-04-15

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1/2 Recruiting
58 enrolled
CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡